Literature DB >> 28031205

In Vitro Activity of Posaconazole against Talaromyces marneffei by Broth Microdilution and Etest Methods and Comparison to Itraconazole, Voriconazole, and Anidulafungin.

Susanna K P Lau1,2,3,4, George C S Lo4, Clare S K Lam5, Wang-Ngai Chow4, Antonio H Y Ngan4, Alan K L Wu6, Dominic N C Tsang7, Cindy W S Tse8, Tak-Lun Que9, Bone S F Tang5, Patrick C Y Woo1,2,3,4.   

Abstract

We determined the susceptibilities of 57 Talaromyces marneffei strains to anidulafungin, itraconazole, voriconazole, and posaconazole with MICs of 2 to 8, 0.002 to 0.004, 0.016 to 0.063, and 0.001 to 0.002 μg/ml by broth microdilution and >32, ≤0.002 to 0.008, ≤0.002 to 0.008, and ≤0.002 μg/ml by Etest, respectively, at yeast phase; MICs at mycelial phase for anidulafungin and posaconazole were 1 to 2 and 0.004 to 0.063 μg/ml, respectively. The results suggest promising activities of posaconazole. Etest can be used for testing of azoles against T. marneffei.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Etest; Penicillium; Talaromyces marneffei; anidulafungin; itraconazole; posaconazole; susceptibility; voriconazole

Mesh:

Substances:

Year:  2017        PMID: 28031205      PMCID: PMC5328531          DOI: 10.1128/AAC.01480-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  First case of Penicillium marneffei fungemia in Greece and strain susceptibility to five licensed systemic antifungal agents and posaconazole.

Authors:  Anna Filiotou; Aristea Velegraki; Markos Giannaris; Maria Pirounaki; Ageliki Mitroussia; Andreas Kaloterakis; Athanassios Archimandritis
Journal:  Am J Med Sci       Date:  2006-07       Impact factor: 2.378

2.  Penicillium marneffei: types and drug susceptibility.

Authors:  P Imwidthaya; K Thipsuvan; A Chaiprasert; S Danchaivijitra; R Sutthent; J Jearanaisilavong
Journal:  Mycopathologia       Date:  2001       Impact factor: 2.574

3.  Serodiagnosis of Penicillium marneffei infection.

Authors:  K Y Yuen; S S Wong; D N Tsang; P Y Chau
Journal:  Lancet       Date:  1994-08-13       Impact factor: 79.321

4.  Pulmonary penicillosis marneffei: report of the first imported case in Canada.

Authors:  A S Sekhon; L Stein; A K Garg; W A Black; J D Glezos; C Wong
Journal:  Mycopathologia       Date:  1994-10       Impact factor: 2.574

5.  In vitro susceptibility of mycelial and yeast forms of Penicillium marneffei to amphotericin B, fluconazole, 5-fluorocytosine and itraconazole.

Authors:  A S Sekhon; A K Garg; A A Padhye; Z Hamir
Journal:  Eur J Epidemiol       Date:  1993-09       Impact factor: 8.082

6.  In vitro activity of anidulafungin against selected clinically important mold isolates.

Authors:  Zekaver Odabasi; Victor L Paetznick; Jose R Rodriguez; Enuo Chen; Luis Ostrosky-Zeichner
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

7.  Susceptibility patterns of clinical and fish isolates of Laribacter hongkongensis: comparison of the Etest, disc diffusion and broth microdilution methods.

Authors:  Susanna K P Lau; Gilman K M Wong; Rosana W S Poon; Leo C K Lee; Kit-Wah Leung; Cindy W S Tse; Pak-Leung Ho; Tak-Lun Que; Patrick C Y Woo; Kwok-Yung Yuen
Journal:  J Antimicrob Chemother       Date:  2009-02-06       Impact factor: 5.790

8.  In vitro antifungal drug susceptibilities of Penicillium marneffei from China.

Authors:  Donghua Liu; Ling Liang; Jimin Chen
Journal:  J Infect Chemother       Date:  2012-10-28       Impact factor: 2.211

9.  In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms.

Authors:  Toru Nakai; Jun Uno; Fumiaki Ikeda; Shuichi Tawara; Kazuko Nishimura; Makoto Miyaji
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

10.  Matrix-assisted laser desorption ionization time-of-flight mass spectrometry for rapid identification of mold and yeast cultures of Penicillium marneffei.

Authors:  Susanna K P Lau; Clare S K Lam; Antonio H Y Ngan; Wang-Ngai Chow; Alan K L Wu; Dominic N C Tsang; Cindy W S Tse; Tak-Lun Que; Bone S F Tang; Patrick C Y Woo
Journal:  BMC Microbiol       Date:  2016-03-10       Impact factor: 3.605

View more
  5 in total

1.  Fevers and Night Sweats in a 35-year-old Man With Recent Travel to Southeast Asia.

Authors:  Matthew S L Lee; Sanjay Kishore; Brian L Hollenbeck; Simi Padival
Journal:  Clin Infect Dis       Date:  2019-10-15       Impact factor: 9.079

Review 2.  Talaromycosis (Penicilliosis) Due to Talaromyces (Penicillium) marneffei: Insights into the Clinical Trends of a Major Fungal Disease 60 Years After the Discovery of the Pathogen.

Authors:  Cunwei Cao; Liyan Xi; Vishnu Chaturvedi
Journal:  Mycopathologia       Date:  2019-12       Impact factor: 2.574

3.  Susceptibility profile of echinocandins, azoles and amphotericin B against yeast phase of Talaromyces marneffei isolated from HIV-infected patients in Guangdong, China.

Authors:  H-L Lei; L-H Li; W-S Chen; W-N Song; Y He; F-Y Hu; X-J Chen; W-P Cai; X-P Tang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-03-13       Impact factor: 3.267

4.  MALDI-TOF MS-Based Clustering and Antifungal Susceptibility Tests of Talaromyces marneffei Isolates from Fujian and Guangxi (China).

Authors:  Lili Fang; Minxue Liu; Chunlan Huang; Jian Guo; Xiaobo Ma; Yanqing Zheng; Wenjuan Wu; Jiangshan Huang; Heping Xu
Journal:  Infect Drug Resist       Date:  2022-07-01       Impact factor: 4.177

5.  Efficacy and Safety of Voriconazole Versus Amphotericin B Deoxycholate Induction Treatment for HIV-Associated Talaromycosis: A Prospective Multicenter Cohort Study in China.

Authors:  Yihong Zhou; Yuanyuan Qin; Yanqiu Lu; Jing Yuan; Jingmin Nie; Min Liu; Qun Tian; Ke Lan; Guoqiang Zhou; Yingmei Qin; Kaiyin He; Jianhua Yu; Zhongsheng Jiang; Jun Liu; Shuiqing Liu; Vijay Harypursat; Yaokai Chen
Journal:  Infect Dis Ther       Date:  2022-06-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.